Atossa Therapeutics, Inc. ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company focused on transforming breast cancer treatment and prevention, announced the completion of a Type C ...

A new study identifies a biological process that empowers specific brain cells to eliminate harmful proteins associated with ...

Scientists at the University of Aberdeen are turning discarded potato stems and leaves, known as “shaws,” into high-value ...

The lights strobed on and off, signaling the start of the annual stroll off – and the boys’ big debut. It would be the first ...

Insilico's generative AI platform, Chemistry42, successfully designed a first-in-class PROTAC targeting PKMYT1 by creating an entirely new inhibitor and its complex linker, demonstrating a powerful, ...

Delve into Vandria's technology and its Alzheimer's candidate, VNA-318, the first mitophagy-based candidate in Alzheimer's in ...

Wockhardt shares surge as US FDA accepts first-ever NDA from an Indian pharma company for new antibiotic Zaynich, aimed at ...

A helpful primer is the way communities approach Web3 loyalty design where engagement is rewarded with collectibles, access tiers and evolving benefits that reflect real input. The lesson is not about ...

Researchers have used precision-engineered nanoparticles to clear toxic proteins from the brains of mice with ...

Good day, everyone, and welcome to today's GitLab Third Quarter Fiscal Year 2026 Conference Call. Please note, this call is being recorded. And it is now my pleasure to turn the conference over to Yao ...

AD is a progressive, relentless disease with Aß and tau as hallmarks. It is caused by a continuous underlying neurotoxic process driven by PF that begins before amyloid plaque accumulation and ...

Long-term LEQEMBI treatment suggests potential to delay disease progression from Mild Cognitive Impairment (MCI) to moderate Alzheimer’s disease by up to 8.3 years in low-amyloid group who started ...